SKSaumya Kasliwal

Saumya Kasliwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saumya Kasliwal has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer

    by Gabriella Baraks, Robert Tseng, Chun-Hao Pan, Saumya Kasliwal, Cindy V. Leiton, Kenneth R. Shroyer, Luisa F. Escobar-Hoyos

    There is an unmet need to identify and validate tumor-specific therapeutic targets to enable more effective treatments for cancer. Heterogeneity in patient clinical characteristics as well as biological and genetic features of tumors present major challenges for the optimization of therapeutic interventions, including the development of novel and more effective precision medicine. The expression of keratin 17 (K17) is a hallmark of the most aggressive forms of cancer across a wide range of anatomical sites and histological types. K17 correlates with shorter patient survival, predicts resistance to specific chemotherapeutic agents, and harbors functional domains that suggest it could be therapeutically targeted. Here, we explore the role of K17 in the hallmarks of cancer and summarize evidence to date for K17-mediated mechanisms involved in each hallmark, elucidating functional roles that warrant further investigation to guide the development of novel therapeutic strategies.

  • Open Access

    Data from Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer

    by Gabriella Baraks, Robert Tseng, Chun-Hao Pan, Saumya Kasliwal, Cindy V. Leiton, Kenneth R. Shroyer, Luisa F. Escobar-Hoyos

    There is an unmet need to identify and validate tumor-specific therapeutic targets to enable more effective treatments for cancer. Heterogeneity in patient clinical characteristics as well as biological and genetic features of tumors present major challenges for the optimization of therapeutic interventions, including the development of novel and more effective precision medicine. The expression of keratin 17 (K17) is a hallmark of the most aggressive forms of cancer across a wide range of anatomical sites and histological types. K17 correlates with shorter patient survival, predicts resistance to specific chemotherapeutic agents, and harbors functional domains that suggest it could be therapeutically targeted. Here, we explore the role of K17 in the hallmarks of cancer and summarize evidence to date for K17-mediated mechanisms involved in each hallmark, elucidating functional roles that warrant further investigation to guide the development of novel therapeutic strategies.

  • Open Access

    Supplementary Table from Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer

    by Gabriella Baraks, Robert Tseng, Chun-Hao Pan, Saumya Kasliwal, Cindy V. Leiton, Kenneth R. Shroyer, Luisa F. Escobar-Hoyos

    Supplementary Table from Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer

  • Open Access

    Supplementary Table from Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer

    by Gabriella Baraks, Robert Tseng, Chun-Hao Pan, Saumya Kasliwal, Cindy V. Leiton, Kenneth R. Shroyer, Luisa F. Escobar-Hoyos

    Supplementary Table from Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer

  • Open Access

    Abstract 2244: Video-based germline testing for individuals with pancreatic ductal adenocarcinoma: Influence of COVID-19 pandemic

    by Saumya Kasliwal, Seyda Baydogan, Devon Harrison, Mark Hurd, Maureen Mork, Anirban Maitra, Florencia McAllister

    Purpose: National guidelines recommend universal germline genetic testing (GT) for patients with Pancreatic Ductal Adenocarcinoma (PDAC), but rates of testing remain low. Given the aggressiveness of PDAC, the window of opportunity for GT is short and often overshadowed by treatment initiation and other clinical milestones. Thus, there is an unmet need for a model that streamlines GT and makes it available to a wider audience in a rapid fashion. Moreover, in pandemic times, video-based alternatives for medical care are increasingly relevant. Methods: We implemented a novel care delivery model in which a seven-minute educational video describing the benefits, risks, and implications of GT was shown to PDAC patients. The video was shown in lieu of an initial consult with a genetic counselor. Only patients who had not undergone GT or previously met with a genetic counselor were included. After watching the video, patients could elect to pursue GT and get tested on-side or remotely (at home). Genetic counselors disclosed results and provided post-test counseling by phone. Clinical and germline data were collected through medical records on a cohort of PDAC patients seen at the Gastrointestinal Center-MD Anderson during a 2-year enrollment period (May 2019-July 2021), which included the COVID-19 pandemic period. Results: A total of 286 PDAC patients watched the educational video. From 175 patients that watched the video pre-pandemic, 12 declined testing, whereas in the post-pandemic period, none of the 111 patients declined testing (6.9% vs 0%; pCitation Format: Saumya Kasliwal, Seyda Baydogan, Devon Harrison, Mark Hurd, Maureen Mork, Anirban Maitra, Florencia McAllister. Video-based germline testing for individuals with pancreatic ductal adenocarcinoma: Influence of COVID-19 pandemic [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2244.

  • Open Access

    Dissecting the Oncogenic Roles of Keratin 17 in the Hallmarks of Cancer

    by Gabriella Baraks, Robert Tseng, Chun-Hao Pan, Saumya Kasliwal, Cindy V. Leiton, Kenneth R. Shroyer, Luisa F. Escobar-Hoyos

    There is an unmet need to identify and validate tumor-specific therapeutic targets to enable more effective treatments for cancer. Heterogeneity in patient clinical characteristics as well as biological and genetic features of tumors present major challenges for the optimization of therapeutic interventions, including the development of novel and more effective precision medicine. The expression of keratin 17 (K17) is a hallmark of the most aggressive forms of cancer across a wide range of anatomical sites and histological types. K17 correlates with shorter patient survival, predicts resistance to specific chemotherapeutic agents, and harbors functional domains that suggest it could be therapeutically targeted. Here, we explore the role of K17 in the hallmarks of cancer and summarize evidence to date for K17-mediated mechanisms involved in each hallmark, elucidating functional roles that warrant further investigation to guide the development of novel therapeutic strategies.